2009 Adverse Analytical Findings and Atypical Findings Reported by Accredited Laboratories. Overview of Results. A Samples. Adverse Analytical

Transcription

1 2009 Findings and Atypical Findings Reported by Accredited Laboratories Overview of Results Table A All Sports Differentiation between Olympic and Non-Olympic Sports A A A A Atypical,3 (%) Findings 2,3 (%) (%) Olympic Sports Non-Olympic Sports TOTAL 187,029 1,674 (0.90%) 2,024 (1.08%) 3,698 (1.98%) 90,899 1,417 (1.56%) 495 (0.54%) 1,912 (2.10%) 277,928 3,091 (1.11%) 2,519 (0.91%) 5,610 (2.02%) 1 The Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti- Doping Rule Violations (ADRV). " Finding " is defined in the World Anti-Doping Code as "a report from a laboratory or other WADA - approved entity that, consistent with the International Standard for Laboratories and related Technical Documents, identifies in a Sample the presence of a Prohibited Substance or its Metabolites or Markers (including elevated quantities of endogenous substances) or evidence of the Use of a Prohibited Method." These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. 2 The Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). "Atypical Finding " is defined in the World Anti-Doping Code as "a report from a laboratory or other WADA-approved entity which requires further investigation as provided by the International Standard for Laboratories or related Technical Documents prior to the determination of an Finding ". Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone. 3 Includes Findings and Atypical Findings

2 2009 Findings and Atypical Findings Reported by Accredited Laboratories Comparison of Years 2003 to 2009 Table A1 Olympic and Non-Olympic Statistics Differentiation between Olympic and Non-Olympic Sports 2003 A 2004 A 2005 A 2006 A 2007 A 2008 A 2009 A A 2009 vs 2008 Olympic Sports Non-Olympic Sports TOTAL 113, , , , , , , % 37,651 40,596 43,501 41,277 49,415 72,548 90, % 151, , , , , , , % Differentiation between Olympic and Non-Olympic Sports AAFs 1,2 AAFs 1,2 AAFs 1,2 AAFs 1,2 AAFs 1, AAFs 1 AAFs vs 2008 Olympic Sports Non-Olympic Sports TOTAL 1,707 2,145 2,958 2,915 3,375 1,974 3,715 1,674 3, % , ,346 1,417 1, % 2,447 2,909 3,909 3,887 4,402 2,956 5,061 3,091 5, % Differentiation between Olympic and Non-Olympic Sports % % % % % % % % % % 2009 AAFs 1 AAFs 1 vs 2008 Olympic Sports Non-Olympic Sports Overall % % % 1 The Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. 2 The Findings (AAF) in years 2003 to 2007 included findings that are defined in 2008 and 2009 as Atypical Findings. 3 Includes Findings and Atypical Findings

3 Table B Laboratory 2009 Findings and Atypical Findings Reported by Accredited Laboratories ( and in ADAMS) Results per Laboratory (All Sports) N N N % N N AAFs 1 reported in AAFs 1 ATFs 2 reported in AAFs 4 ATFs 4 ADAMS 1 Sydney, Australia 6, Seibersdorf, Austria 6, Ghent, Belgium 6, Rio de Janeiro, Brazil 4, Montreal, Canada 16, Beijing, China 15, Bogota, Colombia 2, Havana, Cuba 1, Prague, Czech Republic 1, Helsinki, Finland 2, Paris, France 10, Cologne, Germany 17, Dresden, Germany 8, London, UK 7, Athens, Greece 4, Rome, Italy 15, Tokyo, Japan 7, Seoul, Korea 3, Penang, Malaysia 1, Oslo, Norway 4, Warsaw, Poland 3, Lisbon, Portugal 3, Bloemfontein, South Africa 3, Moscow, Russia 16, Barcelona, Spain 3, Madrid, Spain 7, Stockholm, Sweden 4, Lausanne, Switzerland 6, Bangkok, Thailand 3, Tunis, Tunisia 2, Ankara, Turkey 2, Los Angeles, USA 58, Salt Lake City, USA 13, New Delhi, India 2, Bucharest, Romania 5 1, TOTAL 277,928 3,091 2, % 2,519 2, % ADAMS % 1 The Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. 2 The Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone. 3 Includes Findings and Atypical Findings 4 AAFs and ATFs as compiled from ADAMS 5 Bucharest, Romania laboratory obtained its accreditation in July of 2009

4 Table B Findings and Atypical Findings Reported by Accredited Laboratories Olympic Sports Results per Laboratory Laboratory N N % N Atypical Findings 2 % 1 Sydney, Australia 3, Seibersdorf, Austria 5, Ghent, Belgium 4, Rio de Janeiro, Brazil 4, Montreal, Canada 11, Beijing, China 14, Bogota, Colombia 2, Havana, Cuba 1, Prague, Czech Republic 1, Helsinki, Finland 1, Paris, France 8, Cologne, Germany 14, Dresden, Germany 7, London, UK 5, Athens, Greece 4, Rome, Italy 14, Tokyo, Japan 5, Seoul, Korea 2, Penang, Malaysia 1, Oslo, Norway 3, Warsaw, Poland 2, Lisbon, Portugal 2, Bloemfontein, South Africa 2, Moscow, Russia 15, Barcelona, Spain 3, Madrid, Spain 5, Stockholm, Sweden 2, Lausanne, Switzerland 6, Bangkok, Thailand 1, Tunis, Tunisia 2, Ankara, Turkey 2, Los Angeles, USA 13, Salt Lake City, USA 3, New Delhi, India 2, Bucharest, Romania 1, TOTAL 187,029 1, % 2, % 1 The Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. 2 The Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone. 3 Includes Findings and Atypical Findings

5 Table B Findings and Atypical Findings Reported by Accredited Laboratories Non-Olympic Sports Results per Laboratory Laboratory N N % N Atypical Findings 2 % 1 Sydney, Australia 3, Seibersdorf, Austria Ghent, Belgium 1, Rio de Janeiro, Brazil Montreal, Canada 4, Beijing, China 1, Bogota, Colombia Havana, Cuba Prague, Czech Republic Helsinki, Finland Paris, France 1, Cologne, Germany 2, Dresden, Germany London, UK 2, Athens, Greece Rome, Italy Tokyo, Japan 1, Seoul, Korea Penang, Malaysia Oslo, Norway 1, Warsaw, Poland Lisbon, Portugal Bloemfontein, South Africa 1, Moscow, Russia Barcelona, Spain Madrid, Spain 1, Stockholm, Sweden 1, Lausanne, Switzerland Bangkok, Thailand 1, Tunis, Tunisia Ankara, Turkey Los Angeles, USA 44, Salt Lake City, USA 10, New Delhi, India Bucharest, Romania TOTAL 90,899 1, % % 1 The Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. 2 The Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone. 3 Includes Findings and Atypical Findings

6 Table C Sport 2009 Findings and Atypical Findings Reported by Accredited Laboratories per Sport Olympic Sport Sample Analysis A Sample A Sample Atypical Findings 2 A Sample % Aquatics 13, % Archery % Athletics 26, % Badminton 1, % Basketball 11, % Biathlon 2, % Bobsleigh 1, % Boxing 3, % Canoe / Kayak 3, % Curling % Cycling 21, % Equestrian % Fencing 1, % Football 32, % Gymnastics 2, % Handball 3, % Hockey 2, % Ice Hockey 6, % Judo 4, % Luge % Modern Pentathlon % Rowing 4, % Sailing % Shooting 2, % Skating 4, % Skiing 5, % Table Tennis 1, % Taekwondo 1, % Tennis 3, % Triathlon 3, % Volleyball 5, % Weightlifting 7, % Wrestling 4, % Ice Sport % Hockey/Skating % 187,029 1,674 2,024 3, % 1 The Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. 2 The Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone. 3 Includes Findings and Atypical Findings 4 "Ice Sport"/"Hockey/Skating" was designated on Doping Control Form and therfore unable to assign by single sport or federation.

7 2009 Findings and Atypical Findings Reported by Accredited Laboratories Table D1 Sample Analysis in IOC recognized Sports Sport per Sport Atypical Findings 2 A Sample % Air Sports % Bandy % Baseball 19, % Baseball/Softball % Billiard Sports % Boules % Bowling % Bridge % Chess % Cricket % Dance Sport % Floorball % Golf 1, % Karate 1, % Korfball % Life Saving % Motorcycle Racing % Mountaineering and Climbing % Netball % Orienteering % Pelote Basque % Polo % Powerboating % Racquetball % Rollersports % Rugby 5 5, % Softball 1, % Sport Climbing % Squash % Sumo % Surfing % Tug of War % Underwater Sports % Water Skiing % Wushu % TOTAL 37, % Table D2 Sample Analysis in Paralympic Sports Sport per Sport Atypical Findings 2 A Sample Findings* % Paralympic Sports % 1 The Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. 2 The Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone. 3 Includes Findings and Atypical Findings 4 "Baseball/Softball" was designated on Doping Control Form and therfore unable to assign by single sport or federation. 5 Includes noted as "Rugby" and "Rugby Union".

8 2009 Findings and Atypical Findings Reported by Accredited Laboratories Table D3 Sample Analysis in other Sports Sport per Sport Atypical Findings 2 A Sample % Aikido % American Football 42, % Bodybuilding and Fitness 1, % Casting % Darts % Dragon Boat % Draughts % Fistball % Flying Disc % Go % Ju-Jitsu % Kendo % Kickboxing % Minigolf % Muay Thai % Powerlifting 2, % Sambo % Sepak Takraw % Sleddog % Soft Tennis % Sports Fishing % TOTAL 47, % 1 The Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process. 2 The Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone. 3 Includes Findings and Atypical Findings

9 2009 Findings and Atypical Findings Reported by Accredited Laboratories in ADAMS Table E Number of Prohibited Substances Identified in Each Drug Class (All Sports) Substance Group Number* % of all reported findings* S1. Anabolic Agents 3, % S8. Cannabinoids % S6. Stimulants % S3. Beta-2 Agonists % S5. Diuretics and Other Masking Agents % S9. Glucocorticosteroids % S2. Hormones and Related Substances % S4. Hormone Antagonists and Modulators % P2. Beta-Blockers % S7. Narcotics % M2. Chemical and Physical Manipulation 5 0.1% P2. Alcohol 5 0.1% M1. Enhancement of Oxygen Transfer - 0.0% TOTAL 5,084 *The Findings (AAF) and Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same Athlete. In addition, Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

10 2009 Findings and Atypical Findings Reported by Accredited Laboratories in ADAMS Table F Substances Identified in Each Drug Class (All Sports) S1.1.a. Anabolic Agents - Exogenous AAS Occurences % within drug class Stanozolol % Nandrolone % Methandienone % Metenolone % Boldenone % Mesterolone % Drostanolone % Methyltestosterone % Dehydrochlormethyltestosterone % Oxandrolone % Trenbolone % Oxymetholone 6 0.2% Methasterone 3 0.1% Boldione 3 0.1% Methyltrienolone % Mestanolone % Clostebol % 1-androstenedione % 1-testosterone % 19-norandrostenedione % Fluoxymesterone % subtotal* 681 S1.1.b. Anabolic Agents - Endogenous AAS 1 Occurences % within drug class Testosterone (TE ratio) 2, % Prasterone (DHEA) % Exogenous Steroid(s) by IRMS % Nandrolone metabolite(s) % Androsterone % Epitestosterone 8 0.2% Etiocholanolone 5 0.2% Dihydrotestosterone % subtotal* 2,549 S.1.2 Other Anabolic Agents Occurences % within drug class Clenbuterol % subtotal* 67 S.1. All Anabolic Agents TOTAL* Occurences 3,297 1 Reporting of an Endogenous AAS may be due to detection of a concentration outside normal reference ranges and/or establishment of an exogenous source by GC/C/IRMS. * The Findings (AAF) and Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping i Rule Violations i (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same Athlete. In addition, Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

11 Table F (cont'd) 2009 Findings and Atypical Findings Reported by Accredited Laboratories in ADAMS Substances Identified in Each Drug Class (All Sports) S2. Hormones and Related Substances Occurences % within drug class Erythropoetin (EPO) % Gonadotrophins (hcg) % Mircera (CERA) 8 8.0% Gonadotrophins (LH) 6 6.0% Erythropoetin (Darbepoetin) 4 4.0% Growth Hormone (hgh) 1 1.0% TOTAL* 100 S3. Beta-2 Agonists Occurences % within drug class Terbutaline % Formoterol % Salbutamol % Salmeterol % Fenoterol 5 1.7% Reproterol 3 1.0% Ritodrine 1 0.3% Pirbuterol 1 0.3% TOTAL * 303 S4. Hormone Antagonists and Modulators Occurences % within drug class Tamoxifen % Anastrozole % Clomiphene % Letrozole % Formestane 4 8.0% Exemestane 2 4.0% 6-oxo-androstenedione 2 4.0% Androst-1,4,6-triene-3,17-dione (ATD) 1 2.0% Aminoglutethimide 1 2.0% TOTAL* 50 S5. Diuretics and Other Masking Agents Occurences % within drug class Furosemide % Hydrochlorothiazide % Canrenone % Indapamide % Chlorothiazide % Triamterene % Amiloride 8 2.9% Acetazolamide 8 2.9% Probenecid 7 2.6% Althiazide 3 1.1% Torasemide 2 0.7% Dorzolamide 1 0.4% Bumetanide 1 0.4% Spironolactone 1 0.4% Hydroxyethyl starch (HES) 1 0.4% Bendroflumethiazide 1 0.4% Thiazide 1 0.4% TOTAL * 273 * The Findings (AAF) and Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same Athlete. In addition, Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

12 2009 Findings and Atypical Findings Reported by Accredited Laboratories in ADAMS Table F (cont'd) Substances Identified in Each Drug Class (All Sports) S6. Stimulants Occurences % within drug class Cocaine % Ephedrine % Methylphenidate % Methylhexaneamine (dimethylpentylamine) % Amphetamine % Cathine % Sibutramine % Mephentermine % Isometheptene 9 2.8% Methamphetamine (D-) 9 2.8% 4-phenylpiracetam (carphedon) 8 2.5% Modafinil 8 2.5% D-Amphetamine 8 2.5% Heptaminol 8 2.5% Oxilofrine 6 1.8% Phentermine 6 1.8% Parahydroxyamphetamine 4 1.2% Nikethamide 4 1.2% Fenproporex 3 0.9% Levmetamphetamine 3 0.9% Norfenfluramine 2 0.6% Fenetylline 2 0.6% Octopamine 2 0.6% Phenmetrazine 2 0.6% Methylenedioxymethamphetamine 1 0.3% Tuaminoheptane 1 0.3% Methylephedrine 1 0.3% Strychnine 1 0.3% Pholedrine 1 0.3% Pemoline 1 0.3% Amfrepamone 1 0.3% Bromantan 1 0.3% Methylenedioxyamphetamine 1 0.3% Benzylpiperazine 1 0.3% other 1 0.3% TOTAL* 325 S7. Narcotics Occurences % within drug class Morphine % Oxycodone % Methadone 1 4.2% Hydromorphone 1 4.2% Buprenorphine 1 4.2% TOTAL* 24 * The Findings (AAF) and Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same Athlete. In addition, Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

13 2009 Findings and Atypical Findings Reported by Accredited Laboratories in ADAMS Table F (cont'd) Substances Identified in Each Drug Class (All Sports) S8. Cannabinoids Occurences % within drug class Cannabinoids % TOTAL* 399 S9. Glucocorticosteroids Occurences % within drug class Budesonide % Prednisolone + Prednisone % Betamethasone % Dexamethasone % Prednisolone % Triamcinolone % Methylprednisolone 9 3.4% Desonide 6 2.3% Prednisone 3 1.1% Triamcinolone Acetonide 1 0.4% 16a-hydroxyprednisolone 1 0.4% TOTAL* 265 P1. Alcohol Occurences % within drug class Alcohol % TOTAL* 5 P2. Beta-Blockers Occurences % within drug class Propanolol % Metoprolol % Atenolol % Bisoprolol % Carvedilol 1 2.6% Carteolol 1 2.6% TOTAL* 38 M2. Chemical and Physical Manipulation Occurences % within drug class Manipulation % TOTAL* 5 * The Findings (AAF) and Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same Athlete. In addition, Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone.

14 Laboratory Table G 2009 Findings and Atypical Findings Reported by Accredited Laboratories in ADAMS S1. S2. S3. S4. S5. S6. S7. S8. S9. P1. P2. M2. Anabolic Agents Hormones and Related Substances Laboratory Findings* and Atypical Findings* per Drug Class (All Sports) Beta-2 Agonists Hormone Antagonists and Modulators Diuretics and Other Masking Agents Stimulants Sydney, Australia % Seibersdorf, Austria % Ghent, Belgium % Rio de Janeiro, Brazil % Montreal, Canada % Beijing, China % Bogota, Colombia % Havana, Cuba % Prague, Czech Republic % Helsinki, Finland % Paris, France % Cologne, Germany % Dresden, Germany % London, UK % Athens, Greece % Rome, Italy % Tokyo, Japan % Seoul, Korea % Penang, Malaysia % Oslo, Norway % Warsaw, Poland % Lisbon, Portugal % Bloemfontein, S Africa % Moscow, Russia % Barcelona, Spain % Madrid, Spain % Stockholm, Sweden % Lausanne, Switzerland % Bangkok, Thailand % Tunis, Tunisia % Ankara, Turkey % Los Angeles, USA % Salt Lake City, USA % New Delhi, India % Bucharest, Romania % TOTAL PER DRUG CLASS 3, ,084 % of Drug Class 64.9% 2.0% 6.0% 1.0% 5.4% 6.4% 0.5% 7.8% 5.2% 0.1% 0.7% 0.1% Narcotics Cannabinoids Glucocorticosteroids Alcohol Beta- Blockers Chemical and Physical Manipulation * The Findings (AAF) and Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same Athlete. In addition, Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in the case of longitudinal studies on testosterone. Findings per Lab % of total Findings

15 Table I 2009 Athlete Biological Passport Blood and Reported by Accredited Laboratories in ADAMS per Laboratory (All Sports) N Laboratory 1 Sydney, Australia - 2 Seibersdorf, Austria 70 3 Ghent, Belgium Rio de Janeiro, Brazil - 5 Montreal, Canada 71 6 Beijing, China - 7 Bogota, Colombia - 8 Havana, Cuba - 9 Prague, Czech Republic - 10 Helsinki, Finland - 11 Paris, France - 12 Cologne, Germany 1, Dresden, Germany 6 14 London, UK - 15 Athens, Greece - 16 Rome, Italy Tokyo, Japan - 18 Seoul, Korea - 19 Penang, Malaysia - 20 Oslo, Norway - 21 Warsaw, Poland - 22 Lisbon, Portugal - 23 Bloemfontein, South Africa - 24 Moscow, Russia - 25 Barcelona, Spain - 26 Madrid, Spain Stockholm, Sweden - 28 Lausanne, Switzerland 2, Bangkok, Thailand - 30 Tunis, Tunisia - 31 Ankara, Turkey - 32 Los Angeles, USA - 33 Salt Lake City, USA New Delhi, India - 35 Bucharest, Romania - TOTAL 6,082